Severe community-acquired pneumonia in adults: Current antimicrobial chemotherapy

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 1, 2009, Pages 69-81

  Niven, Daniel J ^a   Laupland, Kevin B ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

Author keywords

Combination therapy; Community acquired pneumonia; Duration; Empiric; Intensive care unit; Severe

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPTOMYCIN; HYPERTENSIVE AGENT; IMIPRAMINE; INOTROPIC AGENT; LINEZOLID; MACROLIDE; MEROPENEM; METICILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BLOOD CULTURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG USE; EARLY INTERVENTION; EMERGENCY CARE; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE; INTERSTITIAL LUNG DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; MYCOSIS; NONHUMAN; RESPIRATORY FAILURE; RESUSCITATION; REVIEW; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; VIRUS PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 69449084452     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.1.69     Document Type: Review

References (91)

1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther. 20(4), 820-837 (1998).
2. Roson B, Carratala J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis. 33(2), 158-165 (2001).
3. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275(2), 134-141 (1996).
4. Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 86(2), 103-111 (2007).
5. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133(3), 610-617 (2008).
6. Baumann WR, Jung RC, Koss M, Boylen CT, Navarro L, Sharma OP. Incidence and mortality of adult respiratory distress syndrome: a prospective analysis from a large metropolitan hospital. Crit. Care Med. 14(1), 1-4 (1986).
7. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58(5), 377-382 (2003).
8. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336(4), 243-250 (1997).
9. Ewig S, Ruiz M, Mensa J et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am. J. Respir. Crit. Care Med. 158(4), 1102-1108 (1998).
10. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34(6), 1589-1596 (2006).
11. Ziss DR, Stowers A, Feild C. Community-acquired pneumonia: compliance with centers for Medicare and Medicaid services, national guidelines, and factors associated with outcome. South. Med. J. 96(10), 949-959 (2003).
12. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am. J. Med. 117(10), 726-731 (2004).
13. Wilson PA, Ferguson J. Severe community-acquired pneumonia: an Australian perspective. Intern. Med. J. 35(12), 699-705 (2005).
14. Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278(23), 2080-2084 (1997).
15. Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch. Intern. Med. 161(17), 2099-2104 (2001).
16. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 164(6), 637-644 (2004).
17. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 127(4), 1260-1270 (2005).
18. Bodi M, Rodriguez A, Sole-Violan J et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin. Infect. Dis. 41(12), 1709-1716 (2005).
19. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 130(1), 11-15 (2006).
20. Silber SH: Garrett C, Singh R et al. Early administration of antibiotics does not shorten time to clinical stability in patients with moderate-to-severe community-acquired pneumonia. Chest 124(5), 1798-1804 (2003).
21. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37(11), 1405-1433 (2003).
22. Aspa J, Rajas O, Rodriguez DC et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur. Respir. J. 27(5), 1010-1019 (2006).
23. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
24. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 159(21), 2562-2572 (1999).
25. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 119(5), 1420-1426 (2001).
26. Menendez R, Ferrando D, Valles JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 122(2), 612-617 (2002).
27. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 123(5), 1503-1511 (2003).
28. Menendez R, Torres A, Zalacain R et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am. J. Respir. Crit. Care Med. 172(6), 757-762 (2005).
29. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31(12), 2742-2751 (2003).
30. Rello J, Catalan M, Diaz E, Bodi M, Alvarez B. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med. 28(8), 1030-1035 (2002).
31. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit. Care Med. 32(3), 625-631 (2004).
32. Yu VL, Chiou CC, Feldman C et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 37(2), 230-237 (2003).
33. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191(12), 2149-2152 (2005).
34. Carcas AJ, Garcia-Satue JL, Zapater P, Frias-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin. Pharmacol. Ther. 65(3), 245-250 (1999).
35. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 128(2), 545-552 (2005).
36. Boselli E, Breilh D, Djabarouti S et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med. 33(9), 1519-1523 (2007).
37. Reinert RR, Reinert S, van der LM, Cil MY, Al Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49(7), 2903-2913 (2005).
38. Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343(26), 1917-1924 (2000).
39. Lujan M, Gallego M, Rello J. Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med. 32(7), 971-980 (2006).
40. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 26(5), 1188-1195. (1998).
41. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin. Infect. Dis. 42(6), 788-797 (2006).
42. Gay K, Baughman W, Miller Y et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J. Infect. Dis. 182(5), 1417-1424 (2000).
43. Morrissey I, Colclough A, Northwood J. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents. Int. J. Antimicrob. Agents 30(4), 345-351 (2007).
44. El Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am. J. Respir. Crit. Care Med. 163(3 Pt 1), 645-651 (2001).
45. Lowy FD. Staphylococcus aureus infections. N. Engl. J. Med. 339(8), 520-532 (1998).
46. Vayalumkal JV, Whittingham H, Vanderkooi O et al. Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments. CJEM 9(4), 300-303 (2007).
47. Al Tawfiq JA, Aldaabil RA. Community-acquired MRSA bacteremic necrotizing pneumonia in a patient with scrotal ulceration. J. Infect. 51(4), E241-E243 (2005).
48. Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton - Valentine leukocidin genes. Clin. Infect. Dis. 40(1), 100-107 (2005).
49. Frazee BW, Salz TO, Lambert L, Perdreau-Remington F. Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia in an immunocompetent young adult. Ann. Emerg. Med. 46(5), 401-404 (2005).
50. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton - Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 128(4), 2732-2738 (2005).
51. Naas T, Fortineau N, Spicq C, Robert J, Jarlier V, Nordmann P. Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton - Valentine leukocidin in a French university hospital. J. Hosp. Infect. 61(4), 321-329 (2005).
52. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290(22), 2976-2984 (2003).
53. Foster TJ. The Staphylococcus aureus "superbug". J. Clin. Invest 114(12), 1693-1696 (2004).
54. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(Suppl. 5), S386-S393 (2008).
55. Plouffe JF, Herbert MT, File TM Jr et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrob. Agents Chemother. 40(5), 1175-1179 (1996).
56. File TM Jr, Segreti J, Dunbar L et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41(9), 1965-1972 (1997).
57. Lode H, File TM Jr, Mandell L, Ball P, Pypstra R, Thomas M. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther. 24(11), 1915-1936 (2002).
58. Frank E, Liu J, Kinasewitz G et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin. Ther. 24(8), 1292-1308 (2002).
59. Frei CR, Koeller JM, Burgess DS, Talbert RL, Johnsrud MT. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy 23(9), 1167-1174 (2003).
60. Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur. Respir. J. 21(1), 135-143 (2003).
61. Mendonca JS, Yamaguti A, Correa JC, Badaro R. Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia. Braz. J. Infect. Dis. 8(1), 90-100 (2004).
62. Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J. Emerg. Med. 27(4), 395-405 (2004).
63. Zervos M, Mandell LA, Vrooman PS et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat. Respir. Med. 3(5), 329-336 (2004).
64. Querol-Ribelles JM, Tenias JM, Querol-Borras JM et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int. J. Antimicrob. Agents 25(1), 75-83 (2005).
65. Garcia VE, Mensa J, Martinez JA et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a β-lactam agent versus a β-lactam agent alone. Eur. J. Clin. Microbiol. Infect. Dis. 24(3), 190-195 (2005).
66. Tamm M, Todisco T, Feldman C et al. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin. Microbiol. Infect. 13(2), 162-171 (2007).
67. Lin TY, Lin SM, Chen HC et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med. J. 30(4), 321-332 (2007).
68. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. 161(15), 1837-1842 (2001).
69. Baddour LM, Yu VL, Klugman KP et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 170(4), 440-444 (2004).
70. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 51(11), 3977-3982 (2007).
71. Rodriguez A, Mendia A, Sirvent JM et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit. Care Med. 35(6), 1493-1498 (2007).
72. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128(1), 172-183 (2005).
73. Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial. Clin. Infect. Dis. 46(10), 1499-1509 (2008).
74. Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 279(18), 1452-1457 (1998).
75. Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37(6), 752-760 (2003).
76. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin. 20(4), 555-563 (2004).
77. Sabria M, Pedro-Botet ML, Gomez J et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 128(3), 1401-1405 (2005).
78. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 108(5), 1288-1291 (1995).
79. Coelho L, Povoa P, Almeida E et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 11(4), R92 (2007).
80. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 174(1), 84-93 (2006).
81. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409), 600-607 (2004).
82. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest 107(5), 1342-1349 (1995).
83. Schutte H, Lohmeyer J, Rosseau S et al. Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur. Respir. J. 9(9), 1858-1867 (1996).
84. Monton C, Torres A, El Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit. Care Med. 27(9), 1745-1753 (1999).
85. Sprung CL, Annane D, Keh D et al. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med. 358(2), 111-124 (2008).
86. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344(10), 699-709 (2001).
87. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit. Care Med. (2007).
88. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2), 238-247 (2003).
89. Confalonieri M, Urbino R, Potena A et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med. 171(3), 242-248 (2005).
90. Laterre PF, Garber G, Levy H et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit. Care Med. 33(5), 952-961 (2005).
91. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21(1), 150-161 (1995).